New resource available  view now

Hope For Alzheimer's patients
and Caregivers

An exciting new clinical trial is evaluating an
investigational treatment for agitation in Alzheimer's

What Are The Symptoms of Agitation ?

Physical aggression:
 e.g., hitting, kicking, biting.

Pacing or aimless wandering:
Repetitive actions or movements (e.g., tapping, fidgeting, rocking).


Verbal outbursts or aggression:
e.g., yelling, cursing, whining.

Destructive behavior:
e.g., earing objects, throwing things, hoarding.


Excessive demands for attention or help.


Restlessness or inability to stay still

What is Agitation in Alzheimer's?

CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of IGC-AD1 for treating agitation associated with Alzheimer’s dementia.

FDA Registered Trial

Clinical Trial Identifier: NCT 05543681
Clinicaltrials.gov:
https://clinicaltrials.gov/study/NCT05543681


Diagnosis of Alzheimer’s Disease.


Symptoms of agitation, aggression, irritability, or restlessness.


Regular behavioral medications are permitted before and during the study.

Have a caregiver who maintains daily contact with the study participant and commits to complying with the study procedures.

  • No cost to participate in the CALMA trial
  • We cover your expenses*
  • Minimal time commitment- Only three clinic visits
  • Receive a blood pressure monitor and weighing scale at no cost
  • A dedicated care team supporting you every step of the way

Take part in groundbreaking research while receiving expert support

  • Up to $500

Information for Families and Caregivers
(Download  English)

Información para Familias y Cuidadores
(Descargar Español)

 

By signing below, the individual (either the potential participant or the caregiver/legal representative) understands and consents to the potential participant’s personal health information (PHI) provided herein may be shared with the study site(s) to determine if they qualify for the clinical trial. The information will be kept private and secure. The individual understands that consent can be withdrawn at any time..
Assess the efficacy of IGC-AD1 on agitation at Week 6.
Assess the efficacy of IGC-AD1 on agitation at Week 2.
  • Assess the efficacy of IGC-AD1 on cognition at Week 6.
  • Measure changes in caregiver burden.
  • Safety and Tolerability  
  • Analyze the biomarker panel. 
  • Daily Logbook with vitals. 

In Clinic

Three visits

Safety Calls

Daily for the first three days.
Afterwards every third day to review safety and compliance.

Please expect an email from our team, we will reach out to you shortly.
📩 Have questions? Contact us at calma@igcpharma.com 

We look forward to your participation in the trial
Find the nearest partner clinic
Enter zip code or your address to identify a clinical site near you

Google Maps Distance and Time Calculator

The CALMA Trial is a clinical research study evaluating an investigational medication for people living with Alzheimer’s disease who are experiencing symptoms of agitation or aggression, which can occur at different stages of the disease and are often very challenging for both patients and caregivers.  The goal is to see whether this new medication can safely and effectively help reduce those symptoms.  

The study drug is safe and tolerable. Still, during phase 1 there were some symptoms reported,   

  • Mild and temporary dizziness that resolves on its own.   
  • Drowsiness (somnolence)   
  • Lack of energy   
  • Falls   
  • Nausea  

Yes, this study will cover transportation services; it could be uber or paying for parking. Also we provide a meal, as the medical visit takes time, (each appointment could take up to 3-4 hours.) 

There will be no charges for participation in this study. The study drug, study related procedures, and study visits will be provided at no cost to you or your insurance company (it is not necessary that you have insurance, and if you have it, there is no issue with it ). 

The total study time is expected to be about 50-57 days or about 8 weeks (including pre-screening, screening, evaluation, study treatment, and follow-up).   

In this study, the participant will be required to take two doses of the study drug daily. However, before starting with the full dose, the participant will take a smaller dose on each of the first two days and on the third day you will take the full dose.  Always during the study there will be clear indications on how to proceed.  

Participation in another clinical trial may affect eligibility for this one. We would need to know more details about the other study to determine whether there’s a potential conflict.  

Yes, the medication being studied is new and considered investigational.  The study drug is an oral solution. It contains two active ingredients, tetrahydrocannabinol (THC) and melatonin.  

A placebo is a substance that looks like real medication but doesn’tcontain any active ingredients. It’s used in clinical trials to help researchers compare and understand the true effects of the investigational drug.  

We work with clinics in several areas. With your zip code or city you can explore in our website the closest clinic.